The SEC filed a settled civil action against Rakesh Ahuja, a former employee of an investment advisory firm, for insider trading based on confidential clinical trial data obtained during employment. Ahuja traded on material nonpublic information on four occasions in connection with three publicly traded biopharmaceutical and biotechnology companies, generating approximately $65,000 in profits. Without admitting or denying the allegations, Ahuja consented to a permanent injunction, a two-year ban from the securities industry, and financial penalties totaling $143,097.51 including disgorgement, prejudgment interest, and a civil penalty.